NCT04516278已完成3 期
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders, NORSE THREE
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 197
- 试验地点
- 21
- 主要终点
- Frequency and incidence of treatment-emergent adverse events
研究概览
简要总结
The study will evaluate the safety of ophthalmic bevacizumab in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Active clinical diagnosis and OCT confirmation of one of the following retinal disorders: exudative age-related macular degeneration (AMD), diabetic macular edema (DME), or branch retinal vein occlusion (BRVO) and, in the opinion of the Investigator, requires treatment with an anti-VEGF therapy
排除标准
- •Previous use of approved anti-VEGF or Avastin® within 4 weeks preceding randomization
- •Macular edema due to something other than exudative AMD, DME or BRVO, in the study eye
- •History of inadequate response to previous intravitreal anti-VEGF therapy
- •History of any intraocular or periocular corticosteroid injection or implant, in the study eye
- •Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-month preceding randomization
- •Any concurrent intraocular condition in the study eye that may require medical or surgical intervention or contribute to vision loss during the study period
- •Active intraocular inflammation in the study eye
- •Current vitreous hemorrhage in the study eye
- •Polypoidal choroidal vasculopathy (PCV) in the study eye
- •History of idiopathic, infectious or autoimmune-associated uveitis in either eye
- •Current ocular or periocular infection, such as conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
- •Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication)
- •Premenopausal women not using adequate contraception
- •Current treatment for active systemic infection
- •Known allergy to any component of the study drug , not amenable to treatment
研究组 & 干预措施
Biological: bevacizumab
Experimental
ONS-5010
干预措施: bevacizumab (Biological)
结局指标
主要结局
Frequency and incidence of treatment-emergent adverse events
时间窗: 3 months
Number of Participants With Adverse Events
时间窗: 3 months
Number of participants with adverse events
次要结局
未报告次要终点
研究者
研究点 (21)
Loading locations...
相似试验
进行中（未招募）
3 期
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal DisordersNeovascular Age-related Macular DegenerationWet Macular DegenerationBRVO - Branch Retinal Vein OcclusionDiabetic Macular EdemaAge-Related Macular DegenerationNCT05112861Outlook Therapeutics, Inc.120
已完成
3 期
Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)Dry Eye DiseaseNCT04567329Bausch & Lomb Incorporated620
已完成
3 期
Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)Dry Eye Disease (DED)NCT04139798Bausch & Lomb Incorporated599
Unknown
不适用
Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.NCT01707745Sivakami A Pai50
已完成
3 期
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)IschemiaCerebrovascular AccidentAtherosclerosisMyocardial InfarctionNCT00617123Merck Sharp & Dohme LLC258